Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus chlorambucil in previously untreated CD20-positive B-cell chronic lymphocytic leukemia
2007-000172-16Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and chlorambucil in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Roche. Primary endpoint: Safety of rituximab plus chlorambucil. Started Jun 2007; status: completed.
02
Drugs
rituximabchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2007-000172-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000172-16.